

FIGURE 1

2/16




FIGURE 2

3/16




FIGURE 3

4/16




FIGURE 4




FIGURE 5

6/16

Interleukine-2 receptor



IL-2 AND IP130 SEQUENCE (α -HELICES ARE BOXED)

FIGURE 6

7/16




FIGURE 7

8/16




FIGURE 8A




FIGURE 8B




FIGURE 8C




FIGURE 8D

9/16




FIGURE 9A





FIGURE 9B

1 APTTSSSTKKKTQLQLLEHLLDLQMLNGINN	10 20 30	% helix (Circular dichroism)	Main molecular species	Activity
1	30	50% (150 à 30µM) 35% (4µM)	Tetramer (4M-8M, Kd=30-100µM) /Octamer	+++
1	10 30	22% (150 à 30µM)	Dimer (1M-2M, Kd=0.2µM) /Tetramer (2M-4M, Kd=100µM)	++
1	22	<2%		-
1	10	0%	Dimer (1M-2M, Kd=50µM) (2M-4M, Kd=1.4mM)	-
5	15	0%	Dimer (1M-2m, Kd=113µM)	-
1	10 20	0%	Monomer	ND
1	20 30	<5%	Monomer	+

FIGURE 10

11/16



IP130

IP130





FIGURE 11

12/16


BLOT ANTI SHC



no stimulation
IL-2 (10 min)
IP130 (1 min)
IP130 (2 min)
IP130 (5 min)
IP130 (10 min)
IP130 (15 min)

FIGURE 12B

BLOT 4G10 (ANTI
PHOSPHOTYROSINE)



no stimulation
IL-2 (10 min)
IP130 (1 min)
IP130 (2 min)
IP130 (5 min)
IP130 (10 min)
IP130 (15 min)

FIGURE 12A

13/16





FIGURE 13



Model of transduction pathway induced by IL-2

FIGURE 14

IL-2 receptor and its major signal transduction pathway

15/16

NK cells (CD56⁺) entering in S+G2/M phases after IP130 stimulation
(synergy with IL-2)


Treatment		J31	J32	J33
IL-2 50 nM		14	12	14
	IP130 60μM	0	17	≤5
	IP130 120μM	0	14	<5
IL-2 50 nM +	IP130 60μM	26	21	7
IL-2 50 nM +	IP130 120μM	28	28	28

FIGURE 15


16/16

Stimulation



3 Days



Effector / target = 10



6 Days



9 Days





FIGURE 16